How a Suppressed JNK Pathway Drives Breast Cancer Resistance

New research published in the Journal of Experimental & Clinical Cancer Research has identified a key mechanism by which ER-positive (ER+) breast cancer cells develop resistance to standard treatments. The study found that the suppression of the c-Jun N-terminal kinase (JNK) signaling pathway, specifically through the loss of the MAP2K7 gene, allows cancer cells to evade therapy and become more aggressive.

The Role of a “Cellular Alarm”

Normally, a combination of endocrine therapy and CDK4/6 inhibitors is highly effective against ER+ breast cancer. However, many patients eventually develop resistance. The JNK pathway acts as a vital “cellular alarm” system that forces cancer cells to undergo stress responses, such as aging and programmed cell death (apoptosis), when under therapeutic pressure.

Using CRISPR/Cas9 gene-editing technology, researchers knocked out genes involved in this pathway in breast cancer cell lines. They discovered that the loss of MAP2K7—a crucial kinase upstream of JNK—disrupts this alarm system. This allows cancer cells to not only survive but also continue to grow and metastasize even when faced with treatment.

Clinical Implications

The findings have significant implications for the clinical management of ER+ breast cancer:

Prognosis and Treatment Response: Analysis of tumor data showed that patients with low JNK signaling activity (indicated by low MAP2K7 and pJNK levels) had a poorer prognosis and were at a higher risk of relapse after treatment.
Personalized Medicine: Assessing the JNK pathway’s activity could serve as a valuable biomarker to identify patients who are unlikely to respond to current standard therapies. This would allow clinicians to select alternative treatment strategies, tailoring care to the individual patient.
Drug Development: The study also serves as a warning for pharmaceutical companies, highlighting the need for precise drug design. Developing drugs that inadvertently suppress the JNK pathway could compromise the effectiveness of other therapies and contribute to the development of resistance.

The research suggests that in the future, checking a tumor’s JNK pathway status could become a critical step in guiding personalized treatment decisions for patients with ER+ breast cancer, helping to improve outcomes and reduce the likelihood of relapse.